Segments of Business and Geographic Areas (Tables)

9 Months Ended

Oct. 01, 2017

Segment Reporting [Abstract]

Sales By Segment Of Business

	Fiscal Third Quarters Ended
(Dollars in Millions)	October 1, 2017		October 2, 2016	Percent Change
Consumer
United States	$	1,285	1,291	(0.5	)%
International	2,071		1,970	5.1
Total	3,356		3,261	2.9
Pharmaceutical
United States	5,816		5,042	15.4
International	3,879		3,358	15.5
Total	9,695		8,400	15.4
Medical Devices
United States	3,189		3,048	4.6
International	3,410		3,111	9.6
Total	6,599		6,159	7.1
Worldwide
United States	10,290		9,381	9.7
International	9,360		8,439	10.9
Total	$	19,650	17,820	10.3	%

	Fiscal Nine Months Ended
(Dollars in Millions)	October 1, 2017		October 2, 2016	Percent Change
Consumer
United States	$	4,186	4,033	3.8	%
International	5,876		5,842	0.6
Total	10,062		9,875	1.9
Pharmaceutical
United States	15,698		15,123	3.8
International	10,877		10,109	7.6
Total	26,575		25,232	5.3
Medical Devices
United States	9,510		9,118	4.3
International	10,108		9,559	5.7
Total	19,618		18,677	5.0
Worldwide
United States	29,394		28,274	4.0
International	26,861		25,510	5.3
Total	$	56,255	53,784	4.6	%

Operating Profit by Segment of Business

	Fiscal Third Quarters Ended
(Dollars in Millions)	October 1, 2017		October 2, 2016	Percent Change
Consumer(1)	$	878	679	29.3	%
Pharmaceutical(2)	2,857		3,309	(13.7	)
Medical Devices(3)	1,383		1,526	(9.4	)
Segments operating profit	5,118		5,514	(7.2	)
Less: Expense not allocated to segments (4)	328		233
Worldwide income before tax	$	4,790	5,281	(9.3	)%

	Fiscal Nine Months Ended
(Dollars in Millions)	October 1, 2017		October 2, 2016	Percent Change
Consumer(1)	$	2,132	1,816	17.4	%
Pharmaceutical(2)	9,934		10,340	(3.9	)
Medical Devices(3)	3,938		4,041	(2.5	)
Segments operating profit	16,004		16,197	(1.2	)
Less: Expense not allocated to segments (4)	891		718
Worldwide income before taxes	$	15,113	15,479	(2.4	)%

(1) Includes a gain of $0.4 billion from the divestiture of COMPEED^® 

(2) Includes a positive adjustment of $0.5 billion to previous reserve estimates in the fiscal nine months of 2016. Includes acquisition costs related to the Actelion acquisition of $0.4 billion and $0.6 billion in the fiscal third quarter and fiscal nine months of 2017, respectively. Includes a gain of $0.2 billion related to monetization of future royalty receivables in the fiscal nine months of 2017. Includes a gain of $0.3 billion and $0.2 billion in the fiscal nine months of 2017 and 2016, respectively, related to the sale of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc.

(3) Includes a restructuring related charge of $0.2 billion and $0.1 billion in the fiscal third quarters of 2017 and 2016, respectively. Includes a restructuring related charge of $0.5 billion and $0.4 billion in the fiscal nine months of 2017 and 2016, respectively. Includes litigation expense of $0.1 billion and $0.1 billion in the fiscal third quarter of 2017 and 2016, respectively. Includes litigation expense of $0.5 billion and $0.7 billion in the fiscal nine months of 2017 and 2016, respectively. Includes an asset impairment of $0.2 billion primarily related to the insulin pump business in the fiscal nine months of 2017.

(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

	Fiscal Third Quarters Ended
(Dollars in Millions)	October 1, 2017		October 2, 2016	Percent Change
United States	$	10,290	9,381	9.7	%
Europe	4,308		3,832	12.4
Western Hemisphere, excluding U.S.	1,569		1,396	12.4
Asia-Pacific, Africa	3,483		3,211	8.5
Total	$	19,650	17,820	10.3	%

	Fiscal Nine Months Ended
(Dollars in Millions)	October 1, 2017		October 2, 2016	Percent Change
United States	$	29,394	28,274	4.0	%
Europe	12,398		11,769	5.3
Western Hemisphere, excluding U.S.	4,522		4,269	5.9
Asia-Pacific, Africa	9,941		9,472	5.0
Total	$	56,255	53,784	4.6	%